Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study.

ABSTRACT:

Background

Regorafenib has been demonstrated as effective in refractory metastatic colorectal cancer. Combination use with chemotherapy has not been reported. We examined the efficacy and safety of adding chemotherapy to Regorafenib for the treatment of metastatic colorectal cancer(mCRC) patients.

Methods

We recruited mCRC patients at our institute who received either regorafenib monotherapy or regorafenib in combination with other chemotherapies. All patients had received chemo and target therapies and presented with disease progression before regorafenib treatment. The primary end point was overall survival.

Findings

Between September1, 2015 and May 31, 2017, 100 mCRC patients at our institute received regorafenib treatment. 39 patients were excluded due to poor per

SUBMITTER: Lin CY 

PROVIDER: S-EPMC5755875 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature